All In Biotech

Drug Trial Radar · NCT02452242

Safety, PK and PD Study of ABX464 in Untreated HIV Patients

A Phase 2, Dose Escalation, Schedule Comparison Study to Evaluate the Safety, Pharmacokinetics, and Viral Kinetics of ABX464 in Untreated Patients With HIV Infection in Mauritius

Last checked: Nov 19, 2026Latest source record: May 30, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

70

Actual

Start

Jan 2015

Primary completion

Dec 2015

Study completion May 2016

Sponsor

Lead sponsor
Abivax S.A.Industry
Sponsor type
Industry
First posted
May 22, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ABX464 is a first in class that showed efficacy as an anti-HIV therapy. The present study is intended to assess the safety, the tolerability, and pharmacokinetic parameters and to evaluate the effect on viral load of repeated oral administrations of ABX464 in patients infected by HIV, not previously treated for their HIV. Two types of design are intended in this protocol: dosing every 3 days or dosing every day. The goal is to determine the best dosing regimen to reduce viral load and minimize adverse events.

Conditions

  • Human Immunodeficiency Virus Infections

Interventions

  • ABX464Drug

    25, 50, 75, 100, 150 mg, i.e. 1, 2, 3, 4 or 6 capsules respectively, every 3 days or every day for 2 weeks

  • PlaceboOther

    1, 2, 3, 4 or 6 capsules respectively, every 3 days or every day for 2 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability profile of ABX464 as assessed by the change from baseline in laboratory values, in vital signs and ECG parameters at week 3 and by the number of patients with adverse events.Time frame: Week 3

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • CAP Research Ltd

    Curepipe, Mauritius

  • HIV-NAT, Thai Red Cross AIDS Research Center

    Bangkok, Thailand

  • Siriraj Hospital, Mahidol University

    Bangkok, Thailand

  • Chiang Mai University

    Chiang Mai, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.